Ticagrelor: The Evidence for Its Clinical Potential as an Oral Antiplatelet Treatment for the Reduction of Major Adverse Cardiac Events in Patients With Acute Coronary Syndromes

Core Evidence - New Zealand

doi 10.2147/ce.s9510